Skinbiotherapeutics Share Discussion Threads

[judijudi] 27/7/2017 19:43

BB's bang on the money!! :)

[onedayrodders] 24/7/2017 15:33

blimey ... lucky call by me

;o)

[ibug] 24/7/2017 10:40

Trading looking brisk this morning ahead of much anticipated news flow. Here are some of the top trades:


10:06 - 24/07 Buy 70734 9.48p £6,702.05

08:01 - 24/07 Buy 50000 8.94p £4,470.00

10:01 - 24/07 Buy 32335 9.25p £2,990.99

10:03 - 24/07 Buy 30000 9.25p £2,775.00

09:09 - 24/07 Buy 30000 9.20p £2,760.00

[rafboy] 24/7/2017 09:22

Only 10k for me this morning but every little helps!

[parob] 24/7/2017 08:04

SOH backed UOM's technology after weighing up various options for investment, and I'm backing him. Look what happened to OPTI! Another 50K for me, rude not to at the IPO price given SOH's family participated in the IPO. John, Thomas and Kate O'Hara bought over 1.25M shares in total. Page 64 of the admission doc:



Would be very surprised if this dropped any lower. We are at, or very close to the bottom IMO.

[ibug] 22/7/2017 20:05

Its all about the definition change about hygiene it is being redefined to include microorganisms and that will create a huge market for SBTX.

[onedayrodders] 22/7/2017 18:06

dunno why but I can feel a change to the upside coming soon

[zedder] 21/7/2017 10:36

Took some money off the table in my IQE holding this morning. Very happy to get 36533 shares at the IPO price.

[ibug] 21/7/2017 09:53

As hygiene is being redefined to include microorganisms it appears the SBTX clinical cream could become widely used by medical professionals as a barrier cream against pathogenic microorganisms...WHICH IS A HUGE MARKET imo.

Cleanliness in context: reconciling hygiene with a modern microbial perspective

This review focuses on the concept of hygiene as it relates to the human-associated microbiota, with the aim of coming to a clear, workable definition of hygiene that is congruent with our emerging understanding of the intimate, multifaceted, and symbiotic relationships that humans have with microorganisms. After conducting a thorough review of peer-reviewed literature on hand hygiene, the skin microbiota, hand washing, and hand drying (compiling over 200 papers), we systematically examined both clinical and commonplace definitions of hygiene and re-evaluated the concept in the context of a modern understanding of human-associated microbial ecology. By doing this, we bridged a gap between the clinical skin microbiology literature and the emerging human-associated microbial ecology literature.

Given the intimate interactions between humans and our microbiota, it is becoming apparent that maintenance and promotion of healthy human-associated microbial communities is necessary for good health. As such, we argue that the concept of hygiene as akin to sterilization no longer serves a useful role in scientific or medical discourse. It is more useful to explicitly define hygiene in terms of health outcomes and focus on the use of quantitative, modern molecular biology tools to elucidate the complex ecological interactions that relate hygienic practice to the spread of disease. Pursuant to that goal, we have explicitly defined hygiene as “those actions and practices that reduce the spread or transmission of pathogenic microorganisms, and thus reduce the incidence of disease.”

[someuwin] 19/7/2017 19:56

Oddly enough, Venture Life Group (LSE:VLG) today released an update which included this bit on their fungal nail product.

"MycoClear

Venture Life also announces that it has filed a patent with the Italian Patent Office on its new MycoClear product for Onychomycosis (fungal nail infection). MycoClear has been developed to deal with both the aesthetic issue of the condition and the underlying infection, which causes discoloured, misshapen nails on both the hands and feet. The European market alone for Onychomycosis products is EUR85m and this product brings innovative design to an area where current products often have low levels of efficacy. As previously announced, the product is already approved as a Class IIa medical device and since that approval, the Company has begun a clinical programme to strengthen the package of data around this product. Early indications from potential partners show a high level of interest in MycoClear and the Company expects to see partnering deals from this product in the next twelve months."


...Not entirely unconnected with SBTX because OPTI and VLG entered into a co-development alliance back in 2015 - although we haven't seen any results from this yet.

[onedayrodders] 19/7/2017 19:39

interesting .. thanks ibug

[ibug] 19/7/2017 15:00

I CONTACTED the company yesterday to ask if their were any plans to produce a cream for fungal infections for toe nails and feet. The CEO replied within a few hours and said they will be definitely investigating fungal infections. If they do produce a cream for that type of infection it will be worth billions because safe and effective treatments have not yet been developed.

Behind the scenes they are likely to be working very hard with the three current projects and they have only been operational for three months. But based on their published plans it cannot be much longer before news breaks giving shareholders better visibility.

Given this sector is high growth and fashionable because it offers alternate treatments without drugs when news does arrive the share price is highly likely to rebound.

[onedayrodders] 19/7/2017 13:31

I said a month ago 7-8p is possible on continued silence.

You cant rush news of course but share price will remain very vulnerable in the absence and MM's wont care about IPO price.

I would add that AIM sentiment and liquidity is very poor currently.

[ibug] 19/7/2017 12:21

Here is the time line we are following, the schedule outline on their website indicates that a steady news flow will happen soon:

[ibug] 19/7/2017 12:16

The thread rodents are posting rubbish again....lol

larva 19 Jul '17 - 12:08 - 499 of 501 0 0 (Filtered)

moneytree1 19 Jul '17 - 12:12 - 500 of 501 0 0 (Filtered)

MAYBE INFA IS A CASH SHELL ABOUT TO BREAK ...lol

[moneytree1] 19/7/2017 12:12

JAM ON SALE TOMORROW

[ibug] 19/7/2017 11:53

The next set of news is likely to be health and safety approval for their clinical cream and the start of clinical field trials.

When that happens the share price should light up imo.

[ibug] 14/7/2017 15:14

OPTI interviewed by TW and SBTX got mentioned....sounded very positive, news coming soon.

[bdog51] 14/7/2017 14:30

Hi Parob, likewise, 11,800 top up for me at 9.06p which is an incredibly low price for SkinBio shares. Didn't expect the share price to drop fully back to IPO purchase price so a great time for topping up. Helped to pull my average down too.Just a question of waiting for news here and then we're off to the races...

[ibug] 14/7/2017 13:49

The Human Microbiome
-The human body has around 10X more bacteria within it, and on it than human cells
-The collective name for all the genes in all the bacteria is 'the microbiome'
-The microbiome consists of around 1000,000 genes – humans have around 23,000
-The microbiome has huge potential to change how the body functions

Skinbiotix

SkinBioTherapeutics uses lysates (extracts) of probiotic bacteria that have been shown to:
-Increase the skins barrier integrity by enhancing the formation of multi-protein complexes called ‘tight junctions’. Tight junctions seal the space between adjacent gut cells to prevent the passage of toxins, molecules and ions through these spaces
-Protect the Skin from infection by outcompeting harmful pathogens
-Increase the rate of Skin healing in response to injury